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Abstract:
Introduction:
Infantile spasms (IS) is an age specific epileptic syndrome. Due to poor
response of IS to conventional antiepileptic drugs, scientists are always on
the lookout for newer, more effective drugs to treat the condition.
Materials & Methods:
In this study, 50 infants with IS symptoms, aged between 2-24 months, were
randomly divided into two equal groups, each treated either with Vigabatrin
or ACTH (long acting Tetracosectide); the results for clinical efficacy of
medication and drug side effects were compared.
Results:
After the sixth week of treatment, in the Vigabatrin group, 28% complete
remission and 40% reduction in seizure frequencies was seen, while in the
Tetracosectide group there were 40.9% complete remission and 45.5%
reduction in seizure frequencies, showing no significant difference between
the clinical responses found in the two groups (P=0.44).
Conclusion:
Vigabatrin effeciacy is similar to Tetracosectide, but since it is impossible to
evaluate visual field constriction, a probable irreversible side effect of Vigabatrin
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Introduction
Infantile spasms(IS), a specific kind of seizure characterized by a series of sudden
muscular contractions in the neck, body and extremities, most commonly develops
between the ages of 3 to 8 months; in about half the patients, we can see normal
mental development up until onset of seizures but in the remainder there is a
definite or a probable delay (1).Mental retardation and cerebral palsy are seen
in 50% and 75% of the patients with infantile spasms respectively (2,3). Incidence
of infantile spasms is between two to five in 10000 live births(4,5). Infantile
spasms can be classified into three clinical (flexor type, extensor type and mixed
type) and three etiologic categories (symptomatic, cryptogenic and idiopathic).
Classic EEG patterns in these patients show hypsarrhythmia characterized by an
irregular unorganized background and also high voltage slow waves and spikes
which are asynchronous and nonrythmic with different duration and topography.
It should be kept in mind that hypsarrhythmia is not a pathognomonic EEG pattern
for IS; in a limited number of patients, clinical spasms are seen without
hypsarrhythmia.
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Infantile spasms are intractable to most conventional
antiepileptic drugs. Since early treatment is necessary for
remission of spasms and to prevent severe neurological
complications,aggressive treatment should be started
immediately following diagnosis(6).
Since 1956, ACTH gel has been successfully used in the
treatment of infantile spasms, and has until now been the
drug of choice; however because of multiple side effects
(hypertension, hyperglycemia, susceptibility to infections,
CNS hemorrhage, etc.) physicians are inclined to use
newer drugs with more efficacy and fewer side effects.
Vigabatrin (VGB) has rapidly gained popularity for the
treatment of infantile spasms because of both its efficacy
and its favorable profile. Chiron et al  1991(7) reported
complete cessation of seizures in 43% of their patients
of all ages afflicted with refractory epilepsy. However,
superiority of VGB to steroids, withregard to efficacy
and side effects has not been studied. Side effects produced
by a steroid are reversible on discontinuation of the drug.
Recent concerns about the seemingly permanent visual
field constriction caused by VGB use makes it diffult for
clinicians to decide between these two drugs. The aim of
this study is to compare the efficacy and side effects of
VGB and ACTH. Since ACTH gel is expensive we treated
our patients with synthetic ACTH (long acting
Tetracosectide).
Materials & Methods
In this study, we enrolled 50 children aged between 2
months and 2 years selected   among  patients with infantile
spasms, who attended the pediatric neurology clinic of
Mofid Children Hospital from Sept 1st 2000 to Sept 1st
2002. The patients were randomized into two equal groups
of 25 cases each; the study group was treated with
Vigabatrin and the controls were treated with synthetic
ACTH (long acting Tetracosectide). In neither group had
patients taken either Steroids or Vigabatrin previously;
some patients had however previously taken conventional
antiepileptic drugs like Phenobarbital , Nitrazepam,
Clonazepam and Pyridoxine without any success. 3
patients in control group were excluded from study during
the first days of study, due to severe drug side effects (2
cases due to severe hypertension and one case due to
severe infection).
All patients were hospitalized for 4 days in order to carry
out paraclinical studies, daily clinical evaluations, to start
the treatment.and to educate family members. The controls
were treated with synthetic ACTH (long - acting
tetracosectide) 1 Iu/kg/day  in one single intramuscular
dose and the case group with oral Vigabatrin 50-100
mg/kg/day  divided into two doses. In both groups, the
drugs were continued for 3 weeks. If there was no
appropriate response, the drug was tapered and
discontinued.  Following an appropriate response, in the
control group, Tetracosectide was continued every other
day for another 3 weeks, after which it was tapered and
discontinued in 10 days, whereas in the study group,
Vigabatrin was continued for about 1 year.
For all patients before starting treatment, paraclinic studies
consisting of EEG, brain CT-scan and laboratory studies
(CBC, BS, Ca, Mg, Na, K, serum lactate, serum ammonia,
blood and urine aminoacid chromatography, urine sugar
chromatography, venous blood gas, TORCH study and
thyroid function tests) were done.
Blood pressure was measured daily during hospitalization
and twice weekly following discharge. Body weight was
measured on the first day of treatment and then after the
3rd and 6th weeks. At the end of the 3rd and 6th weeks,
parents were asked about probable side effects like
somnolence, irritability and abnormal laughing. Patients
were examined for other side effects like cushingoid
appearance, hirsutism and infections.
Clinical criteria for response to treatment was complete
remission of spasms or a decreasing frequency of spasms
(50% reduction compared to the first day of trearment).
Electroencephalogaphic criteria for response to treatment
was partial improvement or complete disappearance of
hypsarrhythmia. For statistical analysis, we used the
Pearson chi-square for comparing qualitative data and
independent sample T-test for comparing quantitative
data. P-value < 0.05 was considered significant.
Results
50 patients were enrolled in the study, with 3 patients
being excluded in the first few days due to severe drug
side effects. Of the 47 remaining, 25 cases (53.2%) or
the study group took Vigabatrin and 22 cases (46.8%) or
the control group took Tetracosectide. Mean age for the
Vigabatrin group was 11 ± 5.3 months or the Tetracosectide
group was 11.5 ± 5, differnce not significant; 23 cases
(48.9%) were male and 24 cases (51.1%) female. From
the etiologic point of view, 34 cases (72.3%) had
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symptomatic IS, while 13 (27.7%) had the cryptogenic
kind. Clinically, 15 cases (31.9%) had the flexor type,
6 (12.8%) the extensor and 26 cases (55.3%) the mixed
type of IS. Neuroimaging studies showed 33 cases
(70.2%) had brain atrophy, 8 cases (17%) normal brain
CT-scans and 6 cases (12.8%) revealed brain structural
disorders.
In the Vigabatrin group, clinical responses to treatment
after 3 weeks were 32% remission of seizures and 44%
reduction in seizure frequency (50%),whereas in the
Tetracosectide group it was 63.6% and 22.7%,
respectively (table I ).
Clinical response to treatment after 6 weeks in Vigabatrin
group, was 28% remission of seizures and 40% reduction
in seizure frequency (50%), and in Tetracosectide group
it was 40.9% and 45.5%, respectively (table II).
The differences between clinical responses in the two
groups after 3 and 6 weeks of treatment were not
significant(P=0.08  and P=0.44, respectively).
EEG results before treatrment in the Vigabatrin group
showed 52% severe abnormality (hypsarrhythmia), 16%
moderate abnormality and 32% mild abnormality, while
in the Tetracosectide group showed 68.2%, 22.7% and
9.1%, of the abnormalities mentioned respectively (table
III).
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EEG results after the treatment in the Vigabatrin group
showed 36% complete recovery, 44% partial improvement
and 20% no improvement; in the Tetracosetide group,
40.9% showed complete recovery, 36.4% partial
improvement and and in 22.7% no improvement was
seen (Table IV)
The differences seen in EEG improvement between the
two groups is not significant(P=0.88).
A probable side effect of Vigabatrin is constriction of
visual field which was not evaluated in our patients;
another side effect of Vigabatrin is laud laughing (8)
which was found in 16% of cases in this group.
31.8% abnormal increase in weight, 25.3% cushingoid
appearance, and 18.2% hypertention were observed in
the Tetracosectide group, not seen in the Vigabatrin
group. The difference between these side effects  in the
two groups is significant. While Hirsutism was seen in
4.5% and susceptibity to infections in 4.5% of cases in
the Tetracosectide group, these side effects were not seen
in the Vigabatrin group(difference between side effects
in the two groups not sigificant)
Overall the side effects  were 16% in the Vigabatrin
group and 81.8% in the Tetracosectide group, a difference
which is significant ( P= 0.001) (Table V).
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Discussion
Different studies compared the efficacy of Vigabatrin
and ACTH, and showed equal efficacy (8) or preference
of ACTH usage(9). In these studies, Vigabatrin had fewer
side effects and was better tolerated by patients (8,9). In
a retrospective, multicenter study (10), VGB was given
as the first treatment at an average dose of 99 mg/kg/day;
complete cessation of spasms was seen in 131 of 192
(68%) patients, and of these 96 (50%) were seizure-free
at follow-up after 0.5-28.6 months. Initial suppression
of spasms was obtained in 68% of infants, and the median
time before a response was 4 days. In contrast to this
study, in another reseach the favorable response rate to
VGB was only 26% (11). VGB was given as the first-
line drug for all patients for 7-20 days; of 42 patients 11
responded to VGB. Ninety-one percent of the infants
responded to a dose of 50-100 mg/kg/day, of which 82%
did so within 1 week. ACTH (3-12 IU/kg) was offered
in combination with VGB to 22 patients for 4-12 weeks
and Valproate to four infants for whom VGB failed.
Eleven of the nonresponders to VGB responded to ACTH
and one to Valproate. The total response rate was 62%.
Our study shows that clinical response and EEG
improvement are similar in the two groups, but as
mentioned in the results, side effects in the Vigabatrin
group are significantly fewer; it must be kept in mind
that side-effects of ACTH are well known by physicians
and are reversible by drug cessation; however we could
not identify the limitation of visual field in infants taking
Vigabatrin, so  we recommended ACTH (long acting
Tetracosectide) as the first choice of treatment for IS,
and encountering  severe side effect, Vigabatrin can
always be used as an effective alternative therapy.
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